IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâ€™s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâ€™s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

06-16	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies	CI
06-16	Irlab highlights positive data for mesdopetam	FW

Market Cap	102M 10.84M 9.36M 8.6M 8.1M 15.21M 1.02B 15.34M 39.68M 502M 40.7M 39.83M 1.74B	P/E 2025 *	-	P/E 2026 *	-
Enterprise Value	102M 10.84M 9.36M 8.6M 8.1M 15.21M 1.02B 15.34M 39.68M 502M 40.7M 39.83M 1.74B	EV / Sales 2025	2.91x	EV / Sales 2026 *	1x
Free-Float	38.17%	Yield 2025 *	-	Yield 2026 *	-

06-16	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies	CI
06-16	Irlab highlights positive data for mesdopetam	FW
06-08	Irlab shares trade ex-rights on Nasdaq Stockholm following rights issue	FW
06-05	IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026	CI
06-05	Irlab rights issue now 91 percent secured	FW
05-06	IRLAB Q1 operating result swings to profit of SEK 10.7 mln	RE
05-06	Irlab reports growth in revenue and operating profit	FW
05-06	IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Verisure climbs on earnings, OMXS30 index gains 1.2 percent	FW
05-05	Eight stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
05-05	Irlab launches SEK 68 million rights issue	FW
05-05	Irlab resolves on rights issue, obtains extended loan financing	RE
04-17	Christer Nordstedt Declines Re-Election as Board Member of IRLAB Therapeutics AB	CI

11-04	Redeye Lowers Fair Value for Irlab to 12 Kronor (from 17)	FW
13/05/24	Irlab rises almost double-digit - Redeye raises motivated value	FW
13/05/24	Redeye raises motivated value for Irlab to SEK 40 (35)	FW
12/02/24	Edison lowers motivated value for Irlab	FW
30/12/23	Bonesupport winner of the year and Viaplay loser of the year on Nasdaq Stockholm 2023	FW

06-16	IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies	AQ
06-16	IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies	AQ
06-05	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received	AQ
06-05	Report from the Extraordinary General Meeting of IRLAB Therapeutics AB	AQ
06-03	IRLAB Participates at Aktiedagarna in Stockholm on June 9	AQ

IRLAB Therapeutics AB Share Price Nasdaq Stockholm

Stocks

Pharmaceuticals

Valuation: IRLAB Therapeutics AB

Latest news : IRLAB Therapeutics AB

Last Transcript: IRLAB Therapeutics AB

Analysts' recommendations: IRLAB Therapeutics AB

Press Releases: IRLAB Therapeutics AB

News in other languages: IRLAB Therapeutics AB

Managers and Directors: IRLAB Therapeutics AB

Other Pharmaceuticals

Financials

Company Profile

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

Manager	Title	Age	Since
Kristina Torfgård CEO	Chief Executive Officer	63	31/07/2024
Susanna Waters PRN	Corporate Officer/Principal	60	31/12/2012
Clas Sonesson CTO	Chief Tech/Sci/R&D Officer	65	31/12/2015

Director	Title	Age	Since
Rein Piir BRD	Director/Board Member	68	31/12/2015
Gunnar Olof Olsson CHM	Chairman	73	06/05/2020
Carola Elisabet Lemne CHM	Chairman	68	19/02/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.71%	-1.80%	+41.03%	+146.90%	1,001B
JOHNSON & JOHNSON	-0.73%	-2.03%	+53.33%	+42.36%	566B
ABBVIE INC.	-0.46%	-1.47%	+19.49%	+60.81%	393B
ROCHE HOLDING AG	+3.82%	+2.29%	+24.04%	+16.53%	326B
NOVARTIS AG	+1.09%	+1.65%	+26.61%	+33.19%	276B
ASTRAZENECA PLC	+1.42%	+0.06%	+26.36%	+15.68%	277B
NOVO NORDISK A/S	+1.87%	+0.87%	-41.49%	-47.26%	193B
AMGEN INC.	-1.04%	+2.22%	+19.02%	+51.02%	188B
GILEAD SCIENCES, INC.	-0.99%	+4.02%	+17.00%	+62.60%	158B
Average	-0.08%	+0.35%	+20.60%	+42.43%	375.2B
Weighted average by Cap.	-0.29%	-0.41%	+29.51%	+66.39%

	2025	2026 *
Net sales	56.3M 5.99M 5.17M 4.75M 4.47M 8.4M 565M 8.47M 21.92M 277M 22.48M 22M 960M	102M 10.85M 9.36M 8.61M 8.1M 15.22M 1.02B 15.35M 39.71M 503M 40.73M 39.86M 1.74B
Net income	-110M -11.67M -10.07M -9.26M -8.71M -16.37M -1.1B -16.51M -42.71M -541M -43.8M -42.87M -1.87B	-32.6M -3.47M -2.99M -2.75M -2.59M -4.87M -327M -4.91M -12.69M -161M -13.02M -12.74M -556M
Net Debt	-	-